Friday, 16 October 2026European Markets

ATOS Stock Bearish By 16% So Far On Wednesday

Loading stream...

(vianews) - shares of atos (cac 40: ato.pa) dropped by a staggering 16.56% to €10.73 at 11:41 est on wednesday, following the last session's upward trend. cac 40 is rising 1.13% to €7,168.55, after two successive sessions in a row of gains. this seems, as yet, an all-around bullish trend trading session today.

about atos

atos se provides digital transformation solutions and services worldwide. it offers cloud, cybersecurity, and computing solutions, as well as end-to-end vertical solutions, data platforms, and infrastructure solutions. the company's solutions include advanced computing; analytics, artificial intelligence, and automation; cloud solutions; customer journey analytics and digital customer experience; advance detection and response, data protection and governance, and trusted digital identities, as well as digital workplace, hybrid cloud, and iot and ot security; digital consulting; digital workplace; and edge computing and internet of things. it also offers infrastructure and foundation services. it serves energy and utilities, financial services and insurance, healthcare and life sciences, manufacturing, public sector and defense, telecommunications and media, transport and logistics, and retail industries. atos se was incorporated in 1982 and is headquartered in bezons, france.

earnings per share

as for profitability, atos has a trailing twelve months eps of €5.05.

pe ratio

atos has a trailing twelve months price to earnings ratio of 2.13. meaning, the purchaser of the share is investing €2.13 for every euro of annual earnings.

volatility

atos's last week, last month's, and last quarter's current intraday variation average was a negative 1.69%, a negative 0.50%, and a positive 3.14%.

atos's highest amplitude of average volatility was 3.13% (last week), 2.66% (last month), and 3.14% (last quarter).

more news about atos (ato.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com